Duzkopru Y, Kocanoglu A, Dogan O, Sahinli H, Cilbir E, Altinbas M. Hemoglobin, albumin, lymphocyte, and platelet score as a predictor of prognosis in metastatic gastric cancer. World J Gastrointest Oncol 2023; 15(9): 1626-1635 [PMID: 37746652 DOI: 10.4251/wjgo.v15.i9.1626]
Corresponding Author of This Article
Yakup Duzkopru, MD, Academic Fellow, Doctor, Department of Medical Oncology, Ankara Etlik City Hospital, Varlik Neighbourhood, Halil Sezai Erkut Street, Yenimahalle, Ankara 06170, Turkey. yakupduzkopru@gmail.com
Research Domain of This Article
Oncology
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Yakup Duzkopru, Abdulkadir Kocanoglu, Ozlem Dogan, Hayriye Sahinli, Ebru Cilbir, Mustafa Altinbas, Department of Medical Oncology, Ankara Etlik City Hospital, Ankara 06170, Turkey
Author contributions: Duzkopru Y and Kocanoglu A performed the study concept, study design, and statistical analysis; Dogan O and Cilbir E contributed to the data acquisition, data analysis and interpretation; Altinbas M and Sahinli H performed the manuscript editing; All authors contributed to the article and approved the submitted version.
Institutional review board statement: The ethics committee approval of the study was given by the Diskapi Yıldırım Beyazıt Training and Research Hospital ethics committee (date: 26.07.2021), No. 116/21.
Informed consent statement: The Institutional Review Board waived the need for informed consent due to the study's retrospective methodology.
Conflict-of-interest statement: The authors declare no conflict of interest.
Data sharing statement: The raw data supporting the conclusions of this article will be made available without restriction by the authors.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yakup Duzkopru, MD, Academic Fellow, Doctor, Department of Medical Oncology, Ankara Etlik City Hospital, Varlik Neighbourhood, Halil Sezai Erkut Street, Yenimahalle, Ankara 06170, Turkey. yakupduzkopru@gmail.com
Received: April 26, 2023 Peer-review started: April 26, 2023 First decision: June 7, 2023 Revised: June 17, 2023 Accepted: July 29, 2023 Article in press: July 29, 2023 Published online: September 15, 2023
Abstract
BACKGROUND
The hemoglobin, albumin, lymphocyte, and platelet (HALP) score, derived from a composite evaluation of markers reflecting the tumor-inflammation relationship and nutritional status, has been substantiated as a noteworthy prognostic determinant for diverse malignancies.
AIM
To investigate how the HALP score relates to prognosis in patients with metastatic gastric cancer.
METHODS
The cutoff values for the HALP score, neutrophil/lymphocyte ratio, and platelet/lymphocyte ratio were determined using receiver operating characteristic analysis. Low HALP scores were defined as those less than 24.79 and high HALP scores as those greater than 24.79.
RESULTS
The study cohort comprised 147 patients and 110 of them (74.8%) were male. The patients' median age was 63 (22-89) years. The median overall survival was significantly superior in the patients with high HALP scores than in those with low HALP scores (10.4 mo vs 7.5 mo, respectively; P < 0.001)
CONCLUSION
The HALP score was found to be a prognostic factor in patients with metastatic gastric cancer.
Core Tip: Median overall survival (OS) was 10.4 mo in the high hemoglobin, albumin, lymphocyte, and platelet (HALP) group and 7.5 mo in the low HALP group. There was a statistically significant difference between the groups in terms of age (P < 0.001), second-line chemotherapy (P < 0.001), sex (P = 0.035), and HALP score (P = 0.004). The HALP score has been demonstrated to be useful as a prognostic factor in a variety of cancer types, including genitourinary and gastrointestinal malignancies. Our study is the first to investigate the HALP score in patients with metastatic gastric cancer. We found that patients with high HALP scores had longer OS. Given its simplicity and low cost, we think the HALP score can be utilized to manage patients with gastric cancer.
